Does REVB pay dividends?

Revelation Biosciences Inc (REVB) does not currently pay a regular dividend.

What is REVB's market cap?

Revelation Biosciences Inc (REVB) has a market capitalization of $4.18M with a current stock price of $1.00.

Revelation Biosciences Inc (REVB)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$1.00

-0.05 (-4.76%)

Market Cap: $4.18M

Last updated: Aug 31, 2026 at 5:00 PM ET

Earnings

Performance (10Y)

Beat Rate

61%(14/23)

Avg Surprise

+6.10%

Upcoming Estimates

Sep 30, 2026

EPS Consensus$-0.88

Range$-0.94 - $-0.82

2 analysts

EPS RevisionsNo revisions (7d)No revisions (30d)

EPS Estimate Drift

90d ago$-0.81+8.5%

60d ago$-0.81+8.5%

30d ago$-0.81+8.5%

7d ago$-0.81+8.5%

Current$-0.88

Revenue Consensus

Range$0 - $0

2 analysts

Dec 31, 2026

EPS Consensus$-2.33

Range$-2.34 - $-2.31

2 analysts

Revenue Consensus

Range$0 - $0

2 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-2.33	$-2.34 - $-2.31	-	-	2	-	-
Sep 30, 2026Sep 26EST	-	$-0.88	$-0.94 - $-0.82	-	-	2	No revisions (30d)	-
Jun 30, 2026Jun 26	$-0.87	$-0.83	$-0.88 - $-0.78	-4.82%	Miss	2	No revisions (30d)	+87.6%
Mar 31, 2026Mar 26	$-2.71	$-1.15	$-1.55 - $-0.75	-135.65%	Miss	2	No revisions (30d)	+89.3%
Dec 31, 2025Dec 25	$-1.65	$-1.41	-	-17.02%	Miss	2	No revisions (30d)	+66.9%
Sep 30, 2025Sep 25	$-7.08	$-5.34	$-5.63 - $-5.05	-32.58%	Miss	2	No revisions (30d)	+95.6%
Jun 30, 2025Jun 25	$-7.01	$-4.46	$-6.15 - $-2.76	-57.17%	Miss	2	2 0 30d	+99.3%
Mar 31, 2025Mar 25	$-25.32	N/A	-	+69.33%	Beat	2	1 0 30d	+94.6%
Dec 31, 2024Dec 24	$-4.98	N/A	-	+51.74%	Beat	2	1 0 30d	+40.2%
Sep 30, 2024Sep 24	$-161.28	N/A	-	+70.42%	Beat	2	No revisions (30d)	+93.5%
Jun 30, 2024Jun 24	$-984.96	$-346.56	$-347.03 - $-346.10	-184.21%	Miss	2	No revisions (30d)	+46.9%
Mar 31, 2024Mar 24	$-472.32	N/A	-	+54.32%	Beat	2	No revisions (30d)	-17029.0%
Dec 31, 2023Dec 23	$-8.33	$-13.77	$-13.77 - $-13.77	+39.51%	Beat	1	1 0 30d	+99.9%
Sep 30, 2023Sep 23	$-2488.78	$-1929.60	$-1929.64 - $-1929.56	-28.98%	Miss	2	No revisions (30d)	+79.4%
Jun 30, 2023Jun 23	$-1854.72	$-1872.00	$-1872.00 - $-1872.00	+0.92%	Beat	1	No revisions (30d)	+92.3%
Mar 31, 2023Mar 23	$2.79	$-0.65	$-0.65 - $-0.65	+529.23%	Beat	1	No revisions (30d)	+100.0%
Dec 31, 2022Dec 22	$-12904.14	$-10080.01	$-10080.01 - $-10080.01	-28.02%	Miss	1	No revisions (30d)	+56.3%
Sep 30, 2022Sep 22	$-12096.03	$-18144.04	$-18144.04 - $-18144.04	+33.33%	Beat	1	No revisions (30d)	-2879907.1%
Jun 30, 2022Jun 22	$-24192.05	$-28224.06	$-28224.06 - $-28224.06	+14.29%	Beat	1	No revisions (30d)	-3313879.5%
Mar 31, 2022Mar 22	$-94752.20	$-28224.06	$-28224.06 - $-28224.06	-235.71%	Beat	1	No revisions (30d)	-59220025.0%
Dec 31, 2021Dec 21	$-29509.83	N/A	-	N/A	Beat	-	-	+17.9%
Sep 30, 2021Sep 21	$-0.42	N/A	-	N/A	Beat	-	-	-
Jun 30, 2021Jun 21	$-0.73	N/A	-	N/A	Beat	-	-	-212.3%
Mar 31, 2021Mar 21	$-0.16	N/A	-	N/A	Beat	-	-	-123.2%
Dec 31, 2020Dec 20	$-35941.58	N/A	-	N/A	Beat	0	No revisions (30d)	-5529573.9%
Sep 30, 2020Sep 20	$0.00	$0.00	-	N/A	Beat	-	-	-100.0%
Dec 31, 2019Dec 19	$0.65	$0.00	$0.00 - $0.00	N/A	Beat	0	No revisions (30d)	+10.2%
Sep 30, 2019Sep 19	$0.69	$0.68	$0.66 - $0.69	+1.47%	Beat	2	No revisions (30d)	+6.2%
Jun 30, 2019Jun 19	$0.65	$0.64	$0.64 - $0.64	+1.56%	Beat	1	1 0 30d	-
Mar 31, 2019Mar 19	$0.62	$0.61	$0.60 - $0.61	+1.64%	Beat	2	No revisions (30d)	-
Dec 31, 2018Dec 18	$0.59	$0.61	$0.60 - $0.61	-3.28%	Miss	2	No revisions (30d)	-
Sep 30, 2018Sep 18	$0.65	$0.65	$0.65 - $0.65	+0.00%	Beat	1	No revisions (30d)	-

Key Metrics

Valuation
P/E Ratio	-0.08	EV/EBITDA	-1.02x
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-154.80%	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	N/A
Current Ratio	6.21x	Quick Ratio	6.21x
Trading Statistics
Beta	-0.17	Avg Volume	42.52K
52-Week High	$11.60	52-Week Low	$0.88

Technical Indicators Dashboard

Moving Averages

SMA 10$1.05

SMA 20$1.09

SMA 50$1.06

SMA 200$1.79

EMA 10$1.04

EMA 20$1.06

EMA 50$1.07

EMA 200$3.58

MACD

Line: -0.01Signal: -0.00Hist: -0.01

ADX

ADX: 15.7+DI: 17.3-DI: 22.9

Aroon & PSAR

Aroon Up40.0

Aroon Down84.0

PSAR$1.19

Bollinger Bands

Upper Band$1.20

Lower Band$0.98

%B Position2044%(Upper)

Band Width0.11

RSI (14-Day)

Neutral

43.9

Momentum Oscillators

Stoch %K39.5

Stoch %D33.7

Williams %R-69.0

ROC (10d)-13.0%

Momentum-0.15

CCI (20d)-109.2

MFI (14d)46.4

Volatility Measures

ATR (14d)$0.08(7.9%)

StdDev (20d)0.06

Hist Vol79.5%(High)

Volume Flow

VWAP$1.02

OBV-58.5M

AD Line11.9B

CMF (20d)-0.118

Volume Metrics

Avg Vol (20d)43.1K

Vol Ratio0.3x(Low)

VWMA (20d)$1.08

Pivot Points

R3$1.17

R2$1.12

R1$1.09

Pivot Point$1.04

S1$1.01

S2$0.96

S3$0.93

Advanced Oscillators

TSI-5.35

Ultimate Osc48.3

KST5.81

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$26,964	$0	$0	$0	$37,574	$0
Cost of Revenue	$0	$0	$5,852	$0	$0	$0	$13,482	$0	$0	$0	$18,787	$0
Gross Profit	$0	$0	$-5,852	$0	$0	$0	$13,482	$0	$0	$0	$18,787	$0

Operating Expenses	$3.66M	$3.09M	$2.57M	$1.94M	$2.46M	$2.09M	$1.75M	$1.80M	$2.52M	$1.90M	$2.33M	$2.78M
R&D	$1.92M	$1.38M	$964,190	$922,857	$1.32M	$858,830	$605,504	$830,981	$1.39M	$717,582	$1.06M	$1.65M
SG&A	$1.74M	$1.72M	$1.61M	$1.02M	$1.14M	$1.24M	$1.15M	$965,705	$1.13M	$1.18M	$1.27M	$1.13M
Operating Income	$-3,662,241	$-3,092,500	$-2,571,587	$-1,943,011	$-2,461,229	$-2,094,987	$-1,753,888	$-1,796,686	$-2,522,397	$-1,902,138	$-2,325,890	$-2,777,897

Interest Income	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$444,879	$5.87M	$779,295	$0	$0
Income Before Tax	$-3,323,384	$-3,009,051	$-2,511,006	$-1,907,176	$-2,444,382	$-2,051,085	$-1,725,719	$-2,241,565	$-8,389,819	$-2,681,433	$-2,202,903	$-2,628,376
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-3,323,384	$-3,009,051	$-2,511,006	$-1,907,176	$-2,444,382	$-2,051,085	$-1,725,719	$-2,241,565	$-8,389,819	$-2,681,433	$-2,202,903	$-2,628,376

EBITDA	$-3,315,071	$-3,001,848	$-2,505,154	$-1,900,411	$-2,437,162	$-2,043,864	$-1,718,498	$-2,234,345	$-8,382,599	$-2,675,171	$-2,196,641	$-2,622,114
EBIT	$-3,323,384	$-3,009,051	$-2,511,006	$-1,907,176	$-2,444,382	$-2,051,085	$-1,725,719	$-2,241,565	$-8,389,819	$-2,681,433	$-2,202,903	$-2,628,376

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about REVB

News

Price to book forward of Revelation Biosciences, Inc. – NASDAQ:REVB

This page displays the "Price to book forward" metric for Revelation Biosciences, Inc. (NASDAQ: REVB). It is a financial data point provided by TradingView, indicating a specific period value and changes for this biotechnology company. The content appears to be a stub or a section of a larger financial data platform.

TradingView•Aug 22, 2026 12:10 PM8/22/26•

Neutral

Price to earnings forward of Revelation Biosciences, Inc. – NASDAQ:REVB

This article provides financial data for Revelation Biosciences, Inc. (NASDAQ: REVB), specifically focusing on its forward price-to-earnings ratio. The content is primarily a data page from TradingView, presenting a section on the company's financial overview without detailed analysis or commentary.

TradingView•Aug 20, 2026 10:40 PM8/20/26•

Neutral

Revelation Biosciences grants restricted stock awards to CEO and CFO

Revelation Biosciences, Inc. (NASDAQ:REVB) has granted restricted stock awards to CEO James Rolke and CFO Chester S. Zygmont, III, under its 2021 Equity Incentive Plan. These awards, totaling 208,076 shares for Rolke and 208,073 for Zygmont, vest in four tranches based on achieving specific market capitalization milestones or continued service over two to four years. The company also recently expanded its Acute Kidney Injury Advisory Board in preparation for a Phase 2/3 clinical trial.

Investing.com•Aug 20, 2026 5:42 AM8/20/26•

Neutral

Revelation Biosciences Grants Performance-Based Restricted Stock to CEO and CFO

Revelation Biosciences, Inc. (NASDAQ: REVB) has granted performance-based Restricted Stock Awards to its CEO, James Rolke (208,076 shares), and CFO, Chester S. Zygmont, III (208,073 shares). These awards, part of the company’s 2021 Equity Incentive Plan, vest in tranches contingent upon Revelation Biosciences achieving specific market capitalization milestones ranging from $30 million to $120 million. This structure aims to align executive incentives directly with shareholder value creation, as the awards only fully vest if the company's valuation significantly increases.

Minichart•Aug 20, 2026 2:40 AM8/20/26•

Bullish

Enterprise value to EBIT forward of Revelation Biosciences, Inc. – NASDAQ:REVB

This article focuses on the enterprise value to EBIT forward for Revelation Biosciences, Inc. (NASDAQ: REVB). It appears to be a financial data page from TradingView, presenting a specific financial metric for the biotechnology company. The content primarily lists navigation and footer information typical of a financial analysis platform.

TradingView•Aug 19, 2026 11:11 PM8/19/26•

Neutral

Frequently Asked Questions About REVB

Does REVB pay dividends?: Revelation Biosciences Inc (REVB) does not currently pay a regular dividend.
What is REVB's market cap?: Revelation Biosciences Inc (REVB) has a market capitalization of $4.18M with a current stock price of $1.00.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In